219 related articles for article (PubMed ID: 20012173)
1. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
2. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
3. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
4. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
5. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
Singh AP; Krzyzanski W; Martin SW; Weber G; Betts A; Ahmad A; Abraham A; Zutshi A; Lin J; Singh P
AAPS J; 2015 Mar; 17(2):389-99. PubMed ID: 25445845
[TBL] [Abstract][Full Text] [Related]
7. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
Marathe A; Krzyzanski W; Mager DE
J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
[TBL] [Abstract][Full Text] [Related]
8. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
9. A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation.
Wu N; Widness JA; Yan X; Veng-Pedersen P; An G
J Pharm Sci; 2022 Sep; 111(9):2620-2629. PubMed ID: 35691608
[TBL] [Abstract][Full Text] [Related]
10. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
Yan X; Ruixo JJP; Krzyzanski W
AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
[TBL] [Abstract][Full Text] [Related]
11. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
12. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
13. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
Wu N; An G
AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
[TBL] [Abstract][Full Text] [Related]
14. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
15. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
[TBL] [Abstract][Full Text] [Related]
16. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
[TBL] [Abstract][Full Text] [Related]
17. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
Gibiansky L; Ng CM; Gibiansky E
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
[TBL] [Abstract][Full Text] [Related]
18. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
19. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
An G
J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
[TBL] [Abstract][Full Text] [Related]
20. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
Grimm HP
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
